NCT05865028View on ClinicalTrials.gov

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

May 24, 2027

Study Completion Date

May 24, 2028

Conditions
Oropharyngeal DysplasiaOral Cavity DysplasiaOral Carcinoma in Situ
Interventions
DRUG

APG-157

Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

Sponsors

Collaborators (1)

Aveta Biomics, Inc.
All Listed Sponsors
collaborator

Aveta Biomics, Inc.

INDUSTRY

lead

Elizabeth J Franzmann

OTHER

NCT05865028 - A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia | Biotech Hunter | Biotech Hunter